Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Issue 6 (2nd June 2016)

• Record Type: Journal Article
• Authors: Kin, Kevin C.; Hill, Dane; Feldman, Steven R.
• Is Part Of: Expert review of clinical pharmacology. Volume 9:Issue 6(2016)
• Page Start: 789
• Page End: 797
• Publication Date: 2016-06-02
• Subjects: Psoriasis -- calcipotriene -- betamethasone dipropionate -- topical; Clinical pharmacology -- Periodicals; 615.105
• DOI: 10.1080/17512433.2016.1179574
• Languages: English
• ISSNs: 1751-2433

Abstract

ABSTRACT: Introduction: Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment. Areas covered: Two-compound calcipotriene and betamethasone dipropionate (BD) is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be effective and safe, with no clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations. Expert commentary: Calcipotriene plus BD is more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. It should be considered a first line therapy for mild-to-moderate plaque psoriasis.